Significance of interleukin-6 (IL-6) in breast cancer (review)
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633 · cited 1×
“There are reports indicating IL-6 as a growth factor in cancer disease for myeloma/plastocytoma, renal cell carcinoma, cervical carcinoma, AIDS Kaposi’s sarcomaderived cells, and certain T- and B-cell lymphomas [18–23].”
BackgroundCytokines in cancer pathogenesis and cancer therapy
Dranoff, G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1252 · Cited by 1,573
Kishimoto, T., Taga, T., & Akira, S. (1994) · Cell · doi:10.1016/0092-8674(94)90333-6 · Cited by 1,328
Interleukin 6 and its receptor: ten years later
Hirano, T. (1998) · International Reviews of Immunology · doi:10.3109/08830189809042997 · Cited by 788 · cited 1×
“Analysis of transgenic mice overexpressing IL-6 in B-cells has shown that IL-6 is involved in the development of plasmacytoma and myeloma [24].”
Background(2000) · PubMed · Cited by 706
Molecular Regulation of B Lymphocyte Response
Kishimoto, T., & Hirano, T. (1988) · Annual Review of Immunology · doi:10.1146/annurev.iy.06.040188.002413 · Cited by 567
AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6.
Miles, S. A., Rezai, A. R., Salazar-González, J. F., Vander Meyden, M., Stevens, R. H., Logan, D. M., Mitsuyasu, R. T., Taga, T., Hirano, T., & Kishimoto, T. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4068 · Cited by 475
Circulating interleukin‐6 predicts survival in patients with metastatic breast cancer
Salgado, R., Junius, S., Benoy, I., Van Dam, P., Vermeulen, P., Van Marck, E., Huget, P., & Dirix, L. Y. (2003) · International Journal of Cancer · doi:10.1002/ijc.10833 · Cited by 435
Interleukin‐6 (IL‐6) functions as an in vitro autocrine growth factor in renal cell carcinomas
Miki, S., Iwano, M., Miki, Y., Yamamoto, M., Tang, B., Yokokawa, K., Sonoda, T., Hirano, T., & Kishimoto, T. (1989) · FEBS Letters · doi:10.1016/0014-5793(89)80805-1 · Cited by 411
Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells.
Conze, D. B., Weiss, L., Regen, P. S., Bhushan, A., Weaver, D. L., Johnson, P. F., & Rincón, M. (2001) · PubMed · Cited by 334
Bachelot, T., Ray-Coquard, I., Menetrier-Caux, C., Rastkha, M., Duc, A., & Blay, J.-Y. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600956 · Cited by 317
Zhang, G.-J., & Adachi, I. (1999) · PubMed · Cited by 306
Ben-Baruch, A. (2002) · Breast Cancer Research · doi:10.1186/bcr554 · Cited by 300
Purohit, A., Newman, S. P., & Reed, M. J. (2002) · Breast Cancer Research · doi:10.1186/bcr425 · Cited by 252
Kozłowski, L., Zakrzewska, I., Tokajuk, P., & Wojtukiewicz, M. Z. (2003) · PubMed · Cited by 248
Aromatase activity and interleukin-6 production by normal and malignant breast tissues
Purohit, A. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.10.3052 · Cited by 201
Marrogi, A. J., Munshi, A., Merogi, A. J., Ohadike, Y., El-Habashi, A., Marrogi, O. L., & Freeman, S. M. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19971021)74:5<492::aid-ijc3>3.0.co;2-z · Cited by 183
Leu, C.-M., Wong, F.-H., Chang, C., Huang, S.-F., & Hu, C.-P. (2003) · Oncogene · doi:10.1038/sj.onc.1207084 · Cited by 168
A possible autocrine role for interleukin-6 in two lymphoma cell lines
Yee, C., Biondi, A., Wang, X., Iscove, N., de Sousa, J., Aarden, L., Wong, G., Clark, S., Messner, H., & Minden, M. (1989) · Blood · doi:10.1182/blood.v74.2.798.798 · Cited by 159
Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond
Esteva, F. J., Valero, V., Pusztai, L., Michaud, L. B., Buzdar, A. U., & Hortobágyi, G. N. (2001) · The Oncologist · doi:10.1634/theoncologist.6-2-133 · Cited by 154
Brocke-Heidrich, K., Kretzschmar, A. K., Pfeifer, G., Henze, C., Löffler, D., Koczan, D., Thiesen, H.-J., Burger, R., Gramatzki, M., & Horn, F. (2004) · Blood · doi:10.1182/blood-2003-04-1048 · Cited by 150
Crichton, M. B., Nichols, J. E., Zhao, Y., Bulun, S. E., & Simpson, E. R. (1996) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(96)03761-6 · Cited by 139
Green, A. R., Green, V. L., White, M. C., & Speirs, V. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970917)72:6<937::aid-ijc3>3.0.co;2-q · Cited by 137
Interleukin-6 (IL-6) Functions as an Autocrine Growth Factor in Cervical Carcinomas in Vitro
Eustace, D. L. S., Han, X., Gooding, R. P., Rowbottom, A. W., Riches, P., & HEYDERMAN, E. (1993) · Gynecologic Oncology · doi:10.1006/gyno.1993.1156 · Cited by 115
Bozcuk, H. S., Uslu, G., Samur, M., Yıldız, M., Özben, T., Özdoğan, M., Artaç, M., Altunbaş, H., Akan, I., & Savaş, B. (2004) · Cytokine · doi:10.1016/j.cyto.2004.04.002 · Cited by 106
THE EFFECTS OF IL-6 ON CELL ADHESION AND E-CADHERIN EXPRESSION IN BREAST CANCER
Asgeirsson, K., Ólafsdóttir, K., Jonasson, J. G., & Ogmundsdottir, H. M. (1998) · Cytokine · doi:10.1006/cyto.1998.0349 · Cited by 101
Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines.
Chiu, J., Sgagias, M. K., & Cowan, K. H. (1996) · PubMed · Cited by 99
Irahara, N., Miyoshi, Y., Taguchi, T., Tamaki, Y., & Noguchi, S. (2006) · International Journal of Cancer · doi:10.1002/ijc.21562 · Cited by 97
Basolo, F., Conaldi, P. G., Fiore, L., Calvo, S., & Toniolo, A. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550609 · Cited by 92
Shen, W. H., Zhou, J. H., Broussard, S. R., Freund, G. G., Dantzer, R., & Kelley, K. W. (2002) · PubMed · Cited by 81
HONMA, S., SHIMODAIRA, K., SHIMIZU, Y., TSUCHIYA, N., SAITO, H., YANAIHARA, T., & OKAI, T. (2002) · Endocrine Journal · doi:10.1507/endocrj.49.371 · Cited by 80
Jabłońska, E., Kiluk, M., Markiewicz, W., Piotrowski, L., Grabowska, Z., & Jablonski, J. (2001) · PubMed · Cited by 80
Shimizu, S., Hirano, T., Yoshioka, R., Sugai, S., Matsuda, T., Taga, T., Kishimoto, T., & Konda, S. (1988) · Blood · doi:10.1182/blood.v72.5.1826.1826 · Cited by 77
García‐Tuñón, I., Ricote, M., Ruiz, A., Fraile, B., Paniagua, R., & Royuela, M. (2005) · Histopathology · doi:10.1111/j.1365-2559.2005.02178.x · Cited by 76
Cytokines facilitate chemotactic motility of breast carcinoma cells
Arihiro, K., Oda, H., Kaneko, M., & Inai, K. (2000) · Breast Cancer · doi:10.1007/bf02967464 · Cited by 71
Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma
Fontanini, G., Campani, D., Roncella, M., Cecchetti, D., Calvo, S., Toniolo, A., & Basolo, F. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690394 · Cited by 67
Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: preliminary report
Yokoe, T., lino, Y., & Morishita, Y. (2000) · Breast Cancer · doi:10.1007/bf02967458 · Cited by 66
Wang, Q.-C., Horiatis, D., & Pinski, J. (2004) · International Journal of Cancer · doi:10.1002/ijc.20286 · Cited by 62
The immune response to breast cancer, and the case for DC immunotherapy
Allan, C. P., Turtle, C. J., Mainwaring, P. N., Pyke, C., & Hart, D. N. J. (2004) · Cytotherapy · doi:10.1080/14653240410005249 · Cited by 59
Jiang, X. P., Yang, D. C., Elliott, R. L., & Head, J. F. (2000) · Cytokine · doi:10.1006/cyto.1999.0591 · Cited by 55
CYP2C and IL-6 expression in breast cancer
Knüpfer, H., Schmidt, R., Stanitz, D., Brauckhoff, M., Schönfelder, M., & Preiß, R. (2003) · The Breast · doi:10.1016/j.breast.2003.07.002 · Cited by 40
Self-citationNishimura, R., 長尾, 和., Miyayama, H., Matsuda, M., Baba, K., Matsuoka, Y., Yamashita, H., Fukuda, M., Mizumoto, T., & Hamamoto, R. (2000) · Oncology · doi:10.1159/000012155 · Cited by 33
Bhat‐Nakshatri, P., Campbell, R. A., Patel, N. M., Newton, T. R., King, A. J., Marshall, M. S., Ali, S., & Nakshatri, H. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601541 · Cited by 30
Verhasselt, B., Damme, J. V., Larebeke, N. V., Put, W., Bracke, M., C, D. P., & Mareel, M. (1992) · PubMed · Cited by 29
Interleukin-6 Upregulates GP96 Expression in Breast Cancer
Haverty, A., Harmey, J. H., Redmond, H. P., & Bouchier‐Hayes, D. J. (1997) · Journal of Surgical Research · doi:10.1006/jsre.1997.5036 · Cited by 26
IN VITRO MODULATION OF CISPLATIN RESISTANCE BY CYTOKINES
Poppenborg, H., Knüpfer, M. M., Galla, H.-J., et al. (1999) · Cytokine · doi:10.1006/cyto.1998.0473 · Cited by 15
Long term survivors of childhood brain cancer have an increased risk for cardiovascular disease
(2000) · Pure Amsterdam UMC · doi:10.1002/(sici)1097-0142(20000501)88:9
Cited by
Tumor Self-Seeding by Circulating Cancer Cells
Kim, M.-Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H.-F., Norton, L., & Massagué, J. (2009) · Cell · doi:10.1016/j.cell.2009.11.025 · Cited by 1,335
Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion
Dirat, B., Bochet, L., Dabek, M., Daviaud, D., Dauvillier, S., Majed, B., Wang, Y. Y., Meulle, A., Salles, B., Le Gonidec, S., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3323 · Cited by 1,134
Cassetta, L., Fragkogianni, S., Sims, A. H., Swierczak, A., Forrester, L. M., Zhang, H., Soong, D. Y. H., Cotechini, T., Anur, P., Lin, E. Y., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.009 · Cited by 920
Marotta, L. L. C., Almendro, V., Marusyk, A., Shipitsin, M., Schemme, J., Walker, S. R., Bloushtain-Qimron, N., Kim, J. J., Choudhury, S. A., Maruyama, R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44745 · Cited by 911
How the ageing microenvironment influences tumour progression
Fane, M., & Weeraratna, A. T. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0222-9 · Cited by 849
Metadata
- Authors
- Knüpfer, H., & Preiß, R.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2006-08-23
- Volume
- 102
- Issue
- 2
- Pages
- 129-135
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W2045352639
- Cited by
- 396
- References
- 47
- FWCI
- 5.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.